FDA 483 - Kite Pharma, Inc.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Kite Pharma, Inc. in El Segundo, CA, from June 12-16, 2017, revealed significant deficiencies in the firm's quality systems. Observations included inadequate written procedures for manufacturing and change control, a lack of validated aseptic processing procedures, and insufficient supplier qualification for critical components. The inspection highlighted several areas requiring improved control over manufacturing processes and quality unit responsibilities.
- Company
- Kite Pharma, Inc.
- Product Type
- Biologics
ID · c9fc9405-6666-4b0e-a9f4-673db6960929